Shots:
- HUTCHMED has completed pts enrollment in P-II trial assessing savolitinib for G/GEJ adenocarcinoma pts (n=64) with MET amplification to evaluate ORR per IRC (1EP) & 2EPs incl. PFS & AE incidence; HUTCHMED plans to file for potential NMPA’s Approval in late 2025
- Interim analysis of the trial showed 45% cORR by IRC & 50% ORR in pts with high MET gene copy number; 4mos. DoR rate was 85.7%, with a mFU of 5.5mos. Data was presented at AACR 2023
- Savolitinib is a MET tyrosine kinase inhibitor co-developed by AstraZeneca and HUTCHMED and is being commercialized by AstraZeneca
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Receives NMPA’s Conditional Approval for Tazverik to Treat R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
